$TZYM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Ocera Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Ocera Therapeutics, Inc.. Get notifications about new insider transactions in Ocera Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 20 2014 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Sell | J | 0.00 | 67,040 | 0 | 136,112 | 203.2 K to 136.1 K (-33.00 %) |
Mar 20 2014 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Sell | J | 0.00 | 338,370 | 0 | 686,994 | 1 M to 687 K (-33.00 %) |
Mar 20 2014 | TZYM | Ocera Therapeutics ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Sell | J | 0.00 | 4,612 | 0 | 9,364 | 14 K to 9.4 K (-33.00 %) |
Mar 20 2014 | TZYM | Ocera Therapeutics ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Sell | J | 0.00 | 67,040 | 0 | 136,112 | 203.2 K to 136.1 K (-33.00 %) |
Mar 20 2014 | TZYM | Ocera Therapeutics ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Sell | J | 0.00 | 338,370 | 0 | 686,994 | 1 M to 687 K (-33.00 %) |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | WIERENGA WENDALL | Director | Option Exercise | A | 13.25 | 20,000 | 265,000 | 20,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | VANLENT ANNE | Director | Option Exercise | A | 7.85 | 20,000 | 157,000 | 20,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | Shah Pratik | Director | Option Exercise | A | 7.85 | 20,000 | 157,000 | 20,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 7.85 | 20,000 | 157,000 | 20,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Option Exercise | A | 7.85 | 20,000 | 157,000 | 20,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | Ekman Lars | Director | Option Exercise | A | 7.85 | 20,000 | 157,000 | 20,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | Castaigne Jean-Paul | Director | Option Exercise | A | 7.85 | 20,000 | 157,000 | 20,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | WEBER ECKARD | Director | Option Exercise | A | 7.85 | 20,000 | 157,000 | 20,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | ROUSSEAU FRANCK | Chief Medical & DEV ... | Option Exercise | A | 7.38 | 226,000 | 1,667,880 | 226,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | HILLEMAN JERYL L | CFO and Secretary | Option Exercise | A | 7.95 | 200,000 | 1,590,000 | 200,000 | |
Dec 23 2013 | TZYM | Ocera Therapeutics ... | Grais Linda S | President and CEO | Option Exercise | A | 7.38 | 491,550 | 3,627,639 | 491,550 | |
Nov 12 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Option Exercise | P | 7.66 | 84,448 | 647,125 | 84,448 | |
Nov 12 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Buy | P | 0.00 | 422,238 | 0 | 1,248,064 | 825.8 K to 1.2 M (+51.13 %) |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Ekman Lars | Director | Option Exercise | A | 1.84 | 2,992 | 5,505 | 2,992 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Ekman Lars | Director | Option Exercise | A | 1.84 | 11,969 | 22,023 | 11,969 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Grais Linda S | President and CEO | Option Exercise | A | 0.67 | 61,653 | 41,308 | 61,653 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Grais Linda S | President and CEO | Option Exercise | A | 0.67 | 11,969 | 8,019 | 11,969 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Option Exercise | A | 1.84 | 2,992 | 5,500 | 2,992 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Option Exercise | A | 1.84 | 2,992 | 5,500 | 2,992 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Option Exercise | A | 2.51 | 11,969 | 30,000 | 11,969 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Option Exercise | A | 0.67 | 5,157 | 3,455 | 5,157 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Option Exercise | A | 0.67 | 5,157 | 3,455 | 5,157 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Buy | P | 6.03 | 431,435 | 2,600,000 | 825,826 | 394.4 K to 825.8 K (+109.39 %) |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | Kjellson Nina S | Director | Grant | A | 0.00 | 394,391 | 0 | 394,391 | 0 to 394.4 K |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 0.67 | 125 | 84 | 125 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 0.67 | 125 | 84 | 125 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 0.67 | 1,820 | 1,219 | 1,820 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 0.67 | 1,820 | 1,219 | 1,820 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 0.67 | 9,187 | 6,155 | 9,187 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 0.67 | 9,187 | 6,155 | 9,187 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 1.84 | 2,992 | 5,505 | 2,992 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 1.84 | 2,992 | 5,505 | 2,992 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | A | 1.25 | 11,969 | 14,961 | 11,969 | |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Buy | P | 6.03 | 4,400 | 26,516 | 13,976 | 9.6 K to 14 K (+45.95 %) |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Buy | J | 0.00 | 9,576 | 0 | 9,576 | 0 to 9.6 K |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Buy | P | 6.03 | 63,957 | 385,430 | 203,152 | 139.2 K to 203.2 K (+45.95 %) |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Buy | J | 0.00 | 139,195 | 0 | 139,195 | 0 to 139.2 K |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Buy | P | 6.03 | 322,809 | 1,945,376 | 1,025,364 | 702.6 K to 1 M (+45.95 %) |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | POWELL MICHAEL | Director | Buy | J | 0.00 | 702,555 | 0 | 702,555 | 0 to 702.6 K |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Buy | P | 6.03 | 4,400 | 26,516 | 13,976 | 9.6 K to 14 K (+45.95 %) |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Buy | P | 6.03 | 63,957 | 385,430 | 203,152 | 139.2 K to 203.2 K (+45.95 %) |
Jul 17 2013 | TZYM | Ocera Therapeutics ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Buy | P | 6.03 | 322,809 | 1,945,376 | 1,025,364 | 702.6 K to 1 M (+45.95 %) |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | WEBER ECKARD | Director | Option Exercise | A | 1.84 | 2,992 | 5,505 | 2,992 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | WEBER ECKARD | Director | Option Exercise | A | 1.84 | 2,992 | 5,505 | 2,992 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | WEBER ECKARD | Director | Option Exercise | A | 0.92 | 11,969 | 11,011 | 11,969 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | WEBER ECKARD | Director | Grant | A | 0.00 | 344,719 | 0 | 344,719 | 0 to 344.7 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | McGowan Dana S. | CFO and Secretary | Option Exercise | A | 0.67 | 4,818 | 3,228 | 4,818 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | McGowan Dana S. | CFO and Secretary | Option Exercise | A | 0.67 | 8,683 | 5,818 | 8,683 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | McGowan Dana S. | CFO and Secretary | Option Exercise | A | 1.84 | 5,984 | 11,011 | 5,984 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | McGowan Dana S. | CFO and Secretary | Option Exercise | A | 1.84 | 5,330 | 9,807 | 5,330 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | McGowan Dana S. | CFO and Secretary | Option Exercise | A | 1.84 | 5,984 | 11,011 | 5,984 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | McGowan Dana S. | CFO and Secretary | Option Exercise | A | 2.51 | 4,488 | 11,265 | 4,488 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | McGowan Dana S. | CFO and Secretary | Option Exercise | A | 1.25 | 17,954 | 22,443 | 17,954 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | McGowan Dana S. | CFO and Secretary | Option Exercise | A | 0.84 | 14,680 | 12,331 | 14,680 | |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | DOVEY BRIAN H | 10% Owner | Buy | P | 6.03 | 331,873 | 1,999,999 | 1,897,336 | 1.6 M to 1.9 M (+21.20 %) |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | DOVEY BRIAN H | 10% Owner | Buy | P | 6.03 | 7,333 | 44,192 | 7,333 | 0 to 7.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | DOVEY BRIAN H | 10% Owner | Buy | P | 6.03 | 988,285 | 5,955,801 | 988,285 | 0 to 988.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | Domain Partners VI, L.P. | 10% Owner | Buy | P | 6.03 | 331,873 | 1,999,999 | 1,897,336 | 1.6 M to 1.9 M (+21.20 %) |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | Halak Brian K | 10% Owner | Buy | P | 6.03 | 331,873 | 1,999,999 | 1,897,336 | 1.6 M to 1.9 M (+21.20 %) |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | Halak Brian K | 10% Owner | Buy | P | 6.03 | 7,333 | 44,192 | 7,333 | 0 to 7.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | Halak Brian K | 10% Owner | Buy | P | 6.03 | 988,285 | 5,955,801 | 988,285 | 0 to 988.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | BLAIR JAMES C | 10% Owner | Buy | P | 6.03 | 331,873 | 1,999,999 | 1,897,336 | 1.6 M to 1.9 M (+21.20 %) |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | BLAIR JAMES C | 10% Owner | Buy | P | 6.03 | 7,333 | 44,192 | 7,333 | 0 to 7.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | BLAIR JAMES C | 10% Owner | Buy | P | 6.03 | 988,285 | 5,955,801 | 988,285 | 0 to 988.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | TREU JESSE I | 10% Owner | Buy | P | 6.03 | 331,873 | 1,999,999 | 1,897,336 | 1.6 M to 1.9 M (+21.20 %) |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | TREU JESSE I | 10% Owner | Buy | P | 6.03 | 7,333 | 44,192 | 7,333 | 0 to 7.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | TREU JESSE I | 10% Owner | Buy | P | 6.03 | 988,285 | 5,955,801 | 988,285 | 0 to 988.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | SCHOEMAKER KATHLEEN K | 10% Owner | Buy | P | 6.03 | 331,873 | 1,999,999 | 1,897,336 | 1.6 M to 1.9 M (+21.20 %) |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | SCHOEMAKER KATHLEEN K | 10% Owner | Buy | P | 6.03 | 7,333 | 44,192 | 7,333 | 0 to 7.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | SCHOEMAKER KATHLEEN K | 10% Owner | Buy | P | 6.03 | 988,285 | 5,955,801 | 988,285 | 0 to 988.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | VITULLO NICOLE | 10% Owner | Buy | P | 6.03 | 331,873 | 1,999,999 | 1,897,336 | 1.6 M to 1.9 M (+21.20 %) |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | VITULLO NICOLE | 10% Owner | Buy | P | 6.03 | 7,333 | 44,192 | 7,333 | 0 to 7.3 K |
Jul 16 2013 | TZYM | Ocera Therapeutics ... | VITULLO NICOLE | 10% Owner | Buy | P | 6.03 | 988,285 | 5,955,801 | 988,285 | 0 to 988.3 K |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | Thomas Helmut | Senior VP, R&D | Option Exercise | A | 4.24 | 90,000 | 381,600 | 90,000 | |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | Eisenstadt Richard I | VP, Finance & CFO | Option Exercise | A | 4.24 | 40,000 | 169,600 | 40,000 | |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | Davidson Aaron | Director | Option Exercise | A | 4.24 | 31,835 | 134,980 | 31,835 | |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | VANLENT ANNE | Director | Option Exercise | A | 4.24 | 31,835 | 134,980 | 31,835 | |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | Castaigne Jean-Paul | Director | Option Exercise | A | 4.24 | 26,448 | 112,140 | 26,448 | |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | ROUSSEAU FRANCK | Chief Medical Offic ... | Option Exercise | A | 4.24 | 8,000 | 33,920 | 8,000 | |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | Garg Vipin K | President & CEO | Option Exercise | A | 4.24 | 50,000 | 212,000 | 50,000 | |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | Zisson Alex | Director | Option Exercise | A | 4.24 | 31,835 | 134,980 | 31,835 | |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | ABERCROMBIE GEORGE B | Director | Option Exercise | A | 4.24 | 31,835 | 134,980 | 31,835 | |
Aug 09 2012 | TZYM | Ocera Therapeutics ... | JOHNSON JOHN | Director | Option Exercise | A | 4.24 | 21,044 | 89,227 | 21,044 | |
Apr 23 2012 | TZYM | Ocera Therapeutics ... | Moore David | VP, Commercial Oper ... | Option Exercise | A | 3.09 | 50,000 | 154,500 | 50,000 | |
Apr 23 2012 | TZYM | Ocera Therapeutics ... | ROUSSEAU FRANCK | Chief Medical Offic ... | Option Exercise | A | 3.09 | 100,000 | 309,000 | 100,000 | |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Brothers Life Sciences C ... | 10% Owner | Buy | P | 3.01 | 34,544 | 103,822 | 3,540,015 | 3.5 M to 3.5 M (+0.99 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Brothers Life Sciences C ... | 10% Owner | Buy | P | 2.99 | 56,294 | 168,268 | 3,505,471 | 3.4 M to 3.5 M (+1.63 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Brothers Life Sciences C ... | 10% Owner | Buy | P | 2.96 | 159,015 | 470,382 | 3,449,177 | 3.3 M to 3.4 M (+4.83 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Brothers Life Sciences C ... | 10% Owner | Buy | P | 2.55 | 572,737 | 1,460,479 | 3,290,162 | 2.7 M to 3.3 M (+21.08 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Brothers Life Sciences C ... | 10% Owner | Buy | P | 2.34 | 327,769 | 766,848 | 2,717,425 | 2.4 M to 2.7 M (+13.72 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Brothers Life Sciences C ... | 10% Owner | Buy | P | 1.87 | 44,467 | 83,153 | 2,389,656 | 2.3 M to 2.4 M (+1.90 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Brothers Life Sciences C ... | 10% Owner | Buy | P | 1.89 | 16,326 | 30,788 | 2,345,189 | 2.3 M to 2.3 M (+0.70 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 3.01 | 4,592 | 13,801 | 232,011 | 227.4 K to 232 K (+2.02 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 2.99 | 7,484 | 22,370 | 227,419 | 219.9 K to 227.4 K (+3.40 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 2.96 | 15,599 | 46,143 | 219,935 | 204.3 K to 219.9 K (+7.63 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 2.55 | 56,187 | 143,277 | 204,336 | 148.1 K to 204.3 K (+37.93 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 2.34 | 32,155 | 75,230 | 148,149 | 116 K to 148.1 K (+27.72 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 1.87 | 4,363 | 8,159 | 115,994 | 111.6 K to 116 K (+3.91 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 1.89 | 1,601 | 3,019 | 111,631 | 110 K to 111.6 K (+1.46 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | 14159 capital (GP), LLC | 10% Owner | Buy | P | 3.01 | 910 | 2,735 | 57,704 | 56.8 K to 57.7 K (+1.60 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | 14159 capital (GP), LLC | 10% Owner | Buy | P | 2.99 | 1,482 | 4,430 | 56,794 | 55.3 K to 56.8 K (+2.68 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | 14159 capital (GP), LLC | 10% Owner | Buy | P | 2.96 | 4,186 | 12,383 | 55,312 | 51.1 K to 55.3 K (+8.19 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | 14159 capital (GP), LLC | 10% Owner | Buy | P | 2.55 | 15,076 | 38,444 | 51,126 | 36.1 K to 51.1 K (+41.82 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | 14159 capital (GP), LLC | 10% Owner | Buy | P | 2.34 | 8,628 | 20,186 | 36,050 | 27.4 K to 36.1 K (+31.46 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | 14159 capital (GP), LLC | 10% Owner | Buy | P | 1.87 | 1,170 | 2,188 | 27,422 | 26.3 K to 27.4 K (+4.46 %) |
Mar 14 2012 | TZYM | Ocera Therapeutics ... | 14159 capital (GP), LLC | 10% Owner | Buy | P | 1.89 | 430 | 811 | 26,252 | 25.8 K to 26.3 K (+1.67 %) |
Oct 21 2011 | TZYM | Ocera Therapeutics ... | ROUSSEAU FRANCK | Chief Medical Offic ... | Option Exercise | A | 2.97 | 175,000 | 519,750 | 175,000 | |
Oct 20 2011 | TZYM | Ocera Therapeutics ... | ABERCROMBIE GEORGE B | Director | Option Exercise | A | 2.97 | 25,000 | 74,250 | 25,000 | |
Oct 04 2011 | TZYM | Ocera Therapeutics ... | Moore David | VP, Commercial Oper ... | Buy | P | 2.58 | 1,050 | 2,709 | 1,050 | 0 to 1.1 K |
Aug 22 2011 | TZYM | Ocera Therapeutics ... | Moore David | VP, Commercial Oper ... | Option Exercise | A | 3.50 | 150,000 | 525,000 | 150,000 | |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | JOHNSON JOHN | Director | Option Exercise | A | 4.00 | 50,000 | 200,000 | 50,000 | |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | Garg Vipin K | President & C.E.O. | Option Exercise | A | 4.00 | 590,089 | 2,360,356 | 590,089 | |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | Eisenstadt Richard I | VP, Finance & C.F.O ... | Option Exercise | A | 4.00 | 148,736 | 594,944 | 148,736 | |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | Gavin Brenda D | Director | Option Exercise | A | 4.00 | 25,000 | 100,000 | 25,000 | |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | Davidson Aaron | Director | Option Exercise | A | 4.00 | 25,000 | 100,000 | 25,000 | |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | Castaigne Jean-Paul | Director | Option Exercise | A | 4.00 | 25,000 | 100,000 | 25,000 | |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | Kosutic Gordana | VP, Clinical and Re ... | Option Exercise | A | 4.00 | 96,192 | 384,768 | 96,192 | |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | VANLENT ANNE | Director | Option Exercise | A | 4.00 | 25,000 | 100,000 | 25,000 | |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | Zisson Alex | Director | Option Exercise | A | 4.00 | 25,000 | 100,000 | 25,000 | |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | QUAKER BIO VENTURES LP | 10% Owner | Option Exercise | C | 0.00 | 15,328,551 | 0 | 0 | |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | QUAKER BIO VENTURES LP | 10% Owner | Buy | P | 4.00 | 375,000 | 1,500,000 | 2,564,791 | 2.2 M to 2.6 M (+17.12 %) |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | QUAKER BIO VENTURES LP | 10% Owner | Buy | C | 0.00 | 2,189,791 | 0 | 2,189,791 | 0 to 2.2 M |
Apr 21 2011 | TZYM | Ocera Therapeutics ... | Thomas Helmut | Senior VP, R&D | Option Exercise | A | 4.00 | 78,641 | 314,564 | 78,641 | |
Apr 07 2011 | TZYM | Ocera Therapeutics ... | Capital regional et cooperatif ... | 10% Owner | Option Exercise | C | 0.00 | 208,052 | 0 | 0 | |
Apr 07 2011 | TZYM | Ocera Therapeutics ... | Capital regional et cooperatif ... | 10% Owner | Option Exercise | C | 0.00 | 8,524,692 | 0 | 0 | |
Apr 07 2011 | TZYM | Ocera Therapeutics ... | Capital regional et cooperatif ... | 10% Owner | Option Exercise | C | 0.00 | 101,482 | 0 | 0 | |
Apr 07 2011 | TZYM | Ocera Therapeutics ... | Capital regional et cooperatif ... | 10% Owner | Buy | C | 0.00 | 29,721 | 0 | 1,262,022 | 1.2 M to 1.3 M (+2.41 %) |
Apr 07 2011 | TZYM | Ocera Therapeutics ... | Capital regional et cooperatif ... | 10% Owner | Buy | C | 0.00 | 1,217,804 | 0 | 1,232,301 | 14.5 K to 1.2 M (+8,400.39 %) |
Apr 07 2011 | TZYM | Ocera Therapeutics ... | Capital regional et cooperatif ... | 10% Owner | Buy | C | 0.00 | 14,497 | 0 | 14,497 | 0 to 14.5 K |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | H.I.G. Ventures - Tranzyme, LL ... | 10% Owner | Option Exercise | C | 0.00 | 15,328,551 | 0 | 0 | |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | H.I.G. Ventures - Tranzyme, LL ... | 10% Owner | Buy | P | 4.00 | 812,500 | 3,250,000 | 3,002,291 | 2.2 M to 3 M (+37.10 %) |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | H.I.G. Ventures - Tranzyme, LL ... | 10% Owner | Buy | C | 0.00 | 2,189,791 | 0 | 2,189,791 | 0 to 2.2 M |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | BDC CAPITAL INC. | 10% Owner | Option Exercise | C | 0.00 | 6,408,016 | 0 | 0 | |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | BDC CAPITAL INC. | 10% Owner | Option Exercise | C | 0.00 | 112,758 | 0 | 0 | |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | BDC CAPITAL INC. | 10% Owner | Option Exercise | C | 0.00 | 2,151,014 | 0 | 0 | |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | BDC CAPITAL INC. | 10% Owner | Buy | P | 4.00 | 1,000,000 | 4,000,000 | 2,238,825 | 1.2 M to 2.2 M (+80.72 %) |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | BDC CAPITAL INC. | 10% Owner | Buy | C | 0.00 | 915,430 | 0 | 1,238,825 | 323.4 K to 1.2 M (+283.07 %) |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | BDC CAPITAL INC. | 10% Owner | Buy | C | 0.00 | 16,108 | 0 | 323,395 | 307.3 K to 323.4 K (+5.24 %) |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | BDC CAPITAL INC. | 10% Owner | Buy | C | 0.00 | 307,287 | 0 | 307,287 | 0 to 307.3 K |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | THOMAS MCNERNEY & PARTNERS LP | 10% Owner | Option Exercise | C | 0.00 | 55,946 | 0 | 0 | |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | THOMAS MCNERNEY & PARTNERS LP | 10% Owner | Option Exercise | C | 0.00 | 547,229 | 0 | 0 | |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | THOMAS MCNERNEY & PARTNERS LP | 10% Owner | Option Exercise | C | 0.00 | 14,725,374 | 0 | 0 | |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | THOMAS MCNERNEY & PARTNERS LP | 10% Owner | Buy | P | 4.00 | 2,966 | 11,864 | 3,002,286 | 3 M to 3 M (+0.10 %) |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | THOMAS MCNERNEY & PARTNERS LP | 10% Owner | Buy | P | 4.00 | 14,568 | 58,272 | 2,999,320 | 3 M to 3 M (+0.49 %) |
Apr 06 2011 | TZYM | Ocera Therapeutics ... | THOMAS MCNERNEY & PARTNERS LP | 10% Owner | Buy | P | 4.00 | 794,966 | 3,179,864 | 2,984,752 | 2.2 M to 3 M (+36.30 %) |